Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 4/20 | 1.00 |
| ▸ | ESR2 | Q92731 | 4/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 9/20 | 0.59 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.56 |
| ▸ | NQO2 | P16083 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | FYN | P06241 | 1/20 | 0.50 |
| ▸ | PGR | P06401 | 1/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL574346 | 1.00 | ESR1 (1.00) | ESR1ESR2PTGS1PTGS2NQO2 | |
| SCHEMBL3988719 | 0.90 | ESR1 (0.82) | ESR1ESR2PTGS1PTGS2NQO2 | |
| SCHEMBL9622832 | 0.90 | ESR1 (0.82) | ESR1ESR2PTGS1PTGS2NQO2 | |
| SCHEMBL3988713 | 0.90 | ESR1 (0.82) | ESR1ESR2PTGS1PTGS2NQO2 | |
| SCHEMBL8393141 | 0.90 | ESR1 (0.82) | ESR1ESR2PTGS1PTGS2NQO2 | |
| SCHEMBL8393139 | 0.90 | ESR1 (0.82) | ESR1ESR2PTGS1PTGS2NQO2 | |
| SCHEMBL5692913 | 0.89 | ESR1 (0.80) | ESR1ESR2PTGS1PTGS2NQO2 | |
| SCHEMBL5692915 | 0.89 | ESR1 (0.80) | ESR1ESR2PTGS1PTGS2NQO2 | |
| SCHEMBL9258161 | 0.84 | ESR1 (0.72) | ESR1ESR2PTGS1PTGS2NQO2 | |
| SCHEMBL9258167 | 0.84 | ESR1 (0.72) | ESR1ESR2PTGS1PTGS2NQO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10577315-B2 | Compositions and methods for treatment of prostate carcinoma | PELLFICURE PHARMACEUTICALS, INC. (US) | 2020-03-03 | — | — | US | disclosed |
| EP-3528799-A1 | PHARMACEUTICAL COMPOSITIONS OF 5-HYDROXY-2-METHYLNAPHTHALENE-1, 4-DIONE | Pellficure Pharmaceuticals, Inc. (US) | 2019-08-28 | — | — | EP | disclosed |
| US-20190169122-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF PROSTATE CARCINOMA | PELLFICURE PHARMACEUTICALS | 2019-06-06 | — | — | US | disclosed |
| WO-2018195202-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | PELLFICURE PHARMACEUTICALS INC. (US) | 2018-10-25 | — | — | WO | disclosed |
| US-10093620-B2 | Compositions and methods for treatment of prostate carcinoma | PELLFICURE PHARMACEUTICALS, INC. (US) | 2018-10-09 | — | — | US | disclosed |
| US-20180221306-A1 | PHARMACEUTICAL COMPOSITIONS OF 5-HYDROXY-2-METHYLNAPHTHALENE-1,4-DIONE | PELLFICURE PHARMACEUTICALS, INC. | 2018-08-09 | — | — | US | disclosed |
| WO-2018080933-A1 | PHARMACEUTICAL COMPOSITIONS OF 5-HYDROXY-2-METHYLNAPHTHALENE-1, 4-DIONE | PELLFICURE PHARMACEUTICALS INC. (US) | 2018-05-03 | — | — | WO | disclosed |
| US-20170283374-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF PROSTATE CARCINOMA | PELLFICURE PHARMACEUTICALS, INC. | 2017-10-05 | — | — | US | disclosed |
| EP-3191087-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF PROSTATE CARCINOMA | Pellficure Pharmaceuticals, Inc. (US) | 2017-07-19 | — | — | EP | disclosed |
| WO-2016040896-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF PROSTATE CARCINOMA | PELLFICURE PHARMACEUTICALS, INC. (US) | 2016-03-17 | — | — | WO | disclosed |
| WO-1995015301-A1 | PREPARATION OF 4,4'-DIHYDROXY-ALPHA-ALKYLSTILBENES AND 4,4'-DIHYDROXY-ALPHA, ALPHA'-DIALKYLSTILBENES | THE DOW CHEMICAL COMPANY (US) | 1995-06-08 | — | — | WO | disclosed |
| US-5382693-A | Curing agents for epoxy resins | THE DOW CHEMICAL COMPANY (US) | 1995-01-17 | — | — | US | disclosed |
| WO-1994026690-A1 | BIS(AMINOPHENOXY)-ALPHA-SUBSTITUTED STILBENES, CURABLE MIXTURES WITH EPOXY RESINS AND CURED PRODUCTS | THE DOW CHEMICAL COMPANY (US) | 1994-11-24 | — | — | WO | disclosed |
| US-5300594-A | Bis(aminophenoxy)-alpha-substituted stilbenes, curable mixtures with epoxy resins and cured products | THE DOW CHEMICAL COMPANY (US) | 1994-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10093620-B2 | Compositions and methods for treatment of prostate carcinoma | KLK3, ACP3, NR5A1 | ESR1 454/4885ESR2 223/4885PTGS1 229/4885 |
| US-20190169122-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF PROSTATE CARCINOMA | KLK3, ACP3, NR5A1 | ESR1 454/4885ESR2 223/4885PTGS1 229/4885 |
| US-20180221306-A1 | PHARMACEUTICAL COMPOSITIONS OF 5-HYDROXY-2-METHYLNAPHTHALENE-1,4-DIONE | DHPS, SRD5A2, SRD5A1 | ESR1 2341/4885ESR2 2002/4885PTGS1 519/4885 |
| US-20170283374-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF PROSTATE CARCINOMA | KLK3, ACP3, NR5A1 | ESR1 454/4885ESR2 223/4885PTGS1 229/4885 |
| US-10577315-B2 | Compositions and methods for treatment of prostate carcinoma | KLK3, ACP3, NR5A1 | ESR1 454/4885ESR2 223/4885PTGS1 229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.